Stock Analysis
- United States
- /
- Biotech
- /
- NasdaqGS:IDYA
IDEAYA Biosciences Third Quarter 2022 Earnings: Beats Expectations
IDEAYA Biosciences (NASDAQ:IDYA) Third Quarter 2022 Results
Key Financial Results- Revenue: US$29.7m (up 231% from 3Q 2021).
- Net income: US$1.62m (up from US$11.6m loss in 3Q 2021).
- Profit margin: 5.4% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue.
- EPS: US$0.04 (up from US$0.31 loss in 3Q 2021).
All figures shown in the chart above are for the trailing 12 month (TTM) period
IDEAYA Biosciences Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates.
Looking ahead, revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
It's necessary to consider the ever-present spectre of investment risk. We've identified 4 warning signs with IDEAYA Biosciences (at least 2 which are a bit concerning), and understanding them should be part of your investment process.What are the risks and opportunities for IDEAYA Biosciences?
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.
Rewards
Revenue is forecast to grow 44.16% per year
Risks
Shareholders have been diluted in the past year
Currently unprofitable and not forecast to become profitable over the next 3 years
Further research on
IDEAYA Biosciences
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqGS:IDYA
IDEAYA Biosciences
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.
Flawless balance sheet with limited growth.
